Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-295.96%
operating margin TTM
-336.15%
revenue TTM
28.77 Million
revenue per share TTM
0.41$
valuation ratios | |
|---|---|
| pe ratio | -1.39 |
| peg ratio | -0.12 |
| price to book ratio | 0.68 |
| price to sales ratio | 4.15 |
| enterprise value multiple | -1.39 |
| price fair value | 0.68 |
profitability ratios | |
|---|---|
| gross profit margin | 82.78% |
| operating profit margin | -336.15% |
| pretax profit margin | -295.6% |
| net profit margin | -295.96% |
| return on assets | -30.12% |
| return on equity | -43.7% |
| return on capital employed | -39.29% |
liquidity ratio | |
|---|---|
| current ratio | 5.71 |
| quick ratio | 5.71 |
| cash ratio | 1.23 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 31.82 |
| days of payables outstanding | 79.10 |
| cash conversion cycle | -47.28 |
| receivables turnover | 11.47 |
| payables turnover | 4.61 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.19 |
| debt equity ratio | 0.30 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.23 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.99 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.93 |
| cash per share | 3.47 |
| operating cash flow per share | -0.92 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.99 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -361.98 |
Frequently Asked Questions
When was the last time C4 Therapeutics, Inc. (NASDAQ:CCCC) reported earnings?
C4 Therapeutics, Inc. (CCCC) published its most recent earnings results on 31-10-2024.
What is C4 Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. C4 Therapeutics, Inc. (NASDAQ:CCCC)'s trailing twelve months ROE is -43.7%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. C4 Therapeutics, Inc. (CCCC) currently has a ROA of -30.12%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CCCC's net profit margin stand at?
CCCC reported a profit margin of -295.96% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CCCC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 5.71 in the most recent quarter. The quick ratio stood at 5.71, with a Debt/Eq ratio of 0.30.